Lempo Therapeutics

Company Overview

Snapshot

Founded in December 2017 by Oren Glanz and Prof. Ben-Zion Garty, Lempo Therapeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its patented gene-editing technology.

Business overview

Lempo Therapeutics is a preclinical biotech company specializing in gene editing to modulate the immune system for the treatment of severe chronic diseases. The company's core technology involves an ex vivo stem cell gene-editing technique designed to minimize immune system-induced collateral damage, thereby mitigating disease progression. Initially targeting pulmonary arterial hypertension (PAH), a rare cardiovascular disease, Lempo Therapeutics operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, and focuses on drug discovery and development.

Company Intelligence Q&A

What is Lempo Therapeutics' primary focus?

Lempo Therapeutics is focused on using gene editing to modify the immune system for attenuating severe chronic diseases, with an initial focus on pulmonary arterial hypertension (PAH).

When was Lempo Therapeutics founded?

Lempo Therapeutics was founded in December 2017.

Who are the founders of Lempo Therapeutics?

Lempo Therapeutics was co-founded by Oren Glanz and Prof. Ben-Zion Garty.

What technology does Lempo Therapeutics utilize?

Lempo Therapeutics utilizes a novel, patented ex vivo stem cell gene-editing technique to minimize collateral damage from immune system activity, aiming to mitigate disease progression.

What diseases has Lempo Therapeutics' concept shown effectiveness in animal models for?

Lempo Therapeutics' concept has shown effectiveness in animal models for the treatment of Alzheimer's disease, multiple sclerosis, and cardiovascular diseases.